Dl-Tryptophan

Dl-Tryptophan

SCHEMBL537138

CC(O)C(N)C(=O)O.NC(Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.80
MAPT P10636 3/20 0.80
KMT2A Q03164 3/20 0.80
LMNA P02545 2/20 0.80
TSHR P16473 2/20 0.80
BLM P54132 2/20 0.80
PMP22 Q01453 2/20 0.80
MEN1 O00255 2/20 0.80
MPO P05164 1/20 0.80
HIF1A Q16665 1/20 0.80
APAF1 O14727 1/20 0.64
POLB P06746 1/20 0.64
RECQL P46063 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.61
HTR2A P28223 3/20 0.58
HTR1A P08908 2/20 0.58
HTR2C P28335 2/20 0.58
SLC6A4 P31645 2/20 0.58
HTR7 P34969 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tryptophan SCHEMBL6268677 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL537140 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL27147785 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL12497478 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL12497474 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL11217425 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL5481922 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL28120361 0.98 KDM4E (0.76) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL7154073 0.96 KDM4E (0.74) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL7859113 0.96 KDM4E (0.74) KDM4EMAPTKMT2ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383840-B1 Extraction of fulvic minerals, vitamins, amino acids, enzymes, and phytonutrients from humic substances MCMAHON GEOFF (US) 2013-02-26 US claimed
CN-117715632-A Compositions comprising an enzyme-cleavable prodrug and nafamostat and methods of use thereof 恩赛斯生物科学股份有限公司 2024-03-15 CN disclosed
WO-2020081525-A1 ELECTROMAGNETIC AND FREQUENCY ENHANCED AGRICULTURE SONIPHI LLC (US) 2020-04-23 WO disclosed
CN-109689085-A COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION 阿塞勒隆制药公司 2019-04-26 CN disclosed
CN-107847561-A TGF- β superfamily type I and type II receptor heteromultimers and uses thereof 阿塞勒隆制药公司 2018-03-27 CN disclosed
CN-104662154-B Use the manufacture method of the lipid of thioesterase variant 花王株式会社 2017-09-01 CN disclosed
US-20170042209-A1 COMPOSITION COMPRISING SACHA INCHI PROTEIN IN COMBINATION WITH OTHER PLANT PROTEINS SHAKLEE CORPORATION 2017-02-16 US disclosed
WO-2017027599-A1 COMPOSITION COMPRISING SACHA INCHI PROTEIN IN COMBINATION WITH OTHER PLANT PROTEINS SHAKLEE CORPORATION (US) 2017-02-16 WO disclosed
CN-103517987-B Change type lipase and manufacture method thereof and use the reaction of this enzyme 宇部兴产株式会社 2016-10-12 CN disclosed
CN-103539831-B Ansu apricot alpha-glucosaccharase enzyme inhibition peptide and its production and use BEIJING FORESTRY UNIVERSITY (CN) 2016-02-03 CN disclosed
CN-101129165-B Pure feed additive of plants ZITAN TANG 2011-11-16 CN disclosed
WO-2010114537-A1 METABOLITES FOR ORAL HEALTH AND USES THEREOF COLGATE-PALMOLIVE COMPANY (US) 2010-10-07 WO disclosed
CN-101129165-A Pure feed additive of plants ZITAN TANG (CN) 2008-02-27 CN disclosed
US-20070118916-A1 Process for the production of fine chemicals METANOMICS GMBH (DE) 2007-05-24 US disclosed
CN-1254484-C Solid-phase synthesis process of octreotide acetate CHANGCHUN LIFEIN PHARMACEUTICA (CN) 2006-05-03 CN disclosed
EP-0975798-A1 METHOD TO DIAGNOSE AND TREAT PATHOLOGICAL CONDITIONS RESULTING FROM DEFICIENT ION TRANSPORT SUCH AS PSEUDOHYPOALDOSTERONISM TYPE-1 YALE UNIVERSITY (US) 2000-02-02 EP disclosed
EP-0946729-A2 PROTEINS WITH ENHANCED LEVELS OF ESSENTIAL AMINO ACIDS PIONEER HI-BRED INTERNATIONAL, INC. (US) 1999-10-06 EP disclosed
US-5888768-A CULTURE PRODUCT; GENETIC ENGINEERING ZYMOGENETICS, INC. (US) 1999-03-30 US disclosed
WO-1998040516-A1 METHOD TO DIAGNOSE AND TREAT PATHOLOGICAL CONDITIONS RESULTING FROM DEFICIENT ION TRANSPORT SUCH AS PSEUDOHYPOALDOSTERONISM TYPE-1 YALE UNIVERSITY (US) 1998-09-17 WO disclosed
WO-1998020133-A2 PROTEINS WITH ENHANCED LEVELS OF ESSENTIAL AMINO ACIDS PIONEER HI-BRED INTERNATIONAL, INC. (US) 1998-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070118916-A1 Process for the production of fine chemicals POLRMT, POLI, POLM KDM4E 3359/4885MAPT 448/4885KMT2A 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.